Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities-Reference-Cited by-同舟云学术

Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities

Published:2006-02 Issue:2 Volume:3 Page:94-103
ISSN:1743-4254
Container-title:Nature Clinical Practice Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Grünhagen Dirk J,de Wilt Johannes HW,ten Hagen Timo LM,Eggermont Alexander MM

Publisher

Springer Science and Business Media LLC

Subject

Oncology,General Medicine

Link

http://www.nature.com/articles/ncponc0426.pdf

Reference74 articles.

1. Creech O Jr et al. (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148: 616–632

2. Benckhuijsen C et al. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14: 157–63

3. Thompson JF and Gianoutsos MP (1992) Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16: 227–233

4. Wieberdink K et al. (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18: 905–910

5. Stotter AT et al. (1990) The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 65: 1119–1129

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PHARMACEUTICAL AND CLINICAL CHALLENGES OF BIOLOGICAL MEDICINES: ONGOING HURDLES FROM DRUG DEVELOPMENT TO THERAPEUTIC APPLICATIONS;Asian Journal of Pharmaceutical and Clinical Research;2024-08-07

2. Isolated Limb Perfusion for Extremity Soft Tissue Sarcoma and Malignant Melanoma;Indian Journal of Surgical Oncology;2024-04-08

3. Combining high throughput array synthesis and growth algorithm to discover TNF-α binders with new structures and properties;European Journal of Medicinal Chemistry;2023-02

4. Tumor Necrosis Factor: What Is in a Name?;Cancers;2022-10-27

5. Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience;Pharmaceutics;2022-10-11